Please assess the completion status of the following clinical trial:

Trial Title: (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* For Part 1: Histologically- or cytologically-confirmed diagnosis of unresectable GIST or another advanced solid tumor. Patients with unresectable GIST must have disease that has progressed following imatinib and at least 1 of the following: sunitinib, regorafenib, sorafenib, dasatinib, pazopanib or an experimental kinase-inhibitor agent, or disease with a D842 mutation in the PDGFRα gene. Patients with an advanced solid tumor other than GIST must have relapsed or refractory disease without an available effective therapy.~OR For Part 2:~* Group 1: Patients must have a confirmed diagnosis of unresectable GIST that has progressed following imatinib and at least 1 of the following: sunitinib, regorafenib, sorafenib, dasatinib, pazopanib, or an experimental kinase-inhibitor agent, and the patient does not have a D842V mutation in PDGFRα.~* Group 2: Patients must have a confirmed diagnosis of unresectable GIST with a D842V mutation in the PDGFRα gene. The PDGFRα mutation will be identified by local or central assessment, either in an archival tissue sample or a new tumor biopsy obtained prior to treatment with avapritinib.~* Group 3: Patients must have a confirmed diagnosis of unresectable GIST that has progressed and/or patients must have experienced intolerance to imatinib and not received additional kinase-inhibitor therapy. Patients must not have a known D842V mutation in PDGFRα.~* Groups 1, 2 and 3: At least 1 measurable lesion defined by mRECIST 1.1 for patients with GIST.~* Groups 1 and 2: A tumor sample (archival tissue or a new tumor biopsy) has been submitted for mutational testing.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2~Exclusion Criteria:~* QT interval corrected using Fridericia's formula (QTcF) \>450 milliseconds~* Platelet count \<90,000/mL~* Absolute neutrophil count \<1000/mL~* Hemoglobin \<9 g/dL~* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>3 x the upper limit of normal (ULN) if no hepatic metastases are present; \>5 × ULN if hepatic metastases are present~* Total bilirubin \>1.5 × ULN; \>3 × ULN with direct bilirubin, \>1.5 × ULN in the presence of Gilbert's Disease~* Estimated (Cockroft-Gault formula) or measured creatinine clearance \<40 mL/min Brain malignancy or metastases to the brain~* History of a seizure disorder or requirement for anti-seizure medication~* Group 3: Patients known to be KIT wild type.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1 Avapritinib (formerly BLU-285) 30 mg QD (Type: EXPERIMENTAL): Part 1: Patients received a starting dose of 30 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation.
- Part 1 Avapritinib (formerly BLU-285) 60 mg QD (Type: EXPERIMENTAL): Part 1: Patients received a starting dose of 60 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation.
- Part 1 Avapritinib (formerly BLU-285) 90 mg QD (Type: EXPERIMENTAL): Part 1: Patients received a starting dose of 90 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation.
- Part 1 Avapritinib (formerly BLU-285) 135 mg QD (Type: EXPERIMENTAL): Part 1: Patients received a starting dose of 135 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation.
- Part 1 Avapritinib (formerly BLU-285) 200 mg QD (Type: EXPERIMENTAL): Part 1: Patients received a starting dose of 200 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation. .
- Part 1 Avapritinib (formerly BLU-285) 300 mg QD (Type: EXPERIMENTAL): Part 1: Patients received a starting dose of 300 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation. Patients that received at least one dose of avapritinib were included in the Part 2 analysis.
- Part 1 Avapritinib (formerly BLU-285) 400 mg QD (Type: EXPERIMENTAL): Part 1: Patients received a starting dose of 400 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation.~Patients that received at least one dose of avapritinib were included in the Part 2 analysis.
- Part 1 Avapritinib (formerly BLU-285) 600 mg QD (Type: EXPERIMENTAL): Part 1: Patients received a starting dose of 600 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation.
- Part 1 and Part 2 Avapritinib (formerly BLU-285) 300 mg or 400 mg QD (Type: EXPERIMENTAL): Part 1 and Part 2: Patients enrolled in Part 1 and Part 2 at a starting dose of 300 or 400 mg QD were included in the Part1/Part 2 safety and efficacy analysis.~Patients received avapritinib in continuous 28 day cycles until discontinuation.

Based on this trial design, predict the completion outcome and termination type (if applicable).